Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
European regulator endorses approving Leclaza combo therapy to treat NSCLC
EMA's CHMP recommended approval of Leclaza (lazertinib) and Rybrevant (amivantamab) for first-line NSCLC treatment, pending EMA decision by late 2024 or early 2025. The combination showed longer progression-free survival but higher adverse events.
Atopic Dermatitis Market 2024: Key Trends, Innovations, and Growth Forecast
The atopic dermatitis market is projected to grow from $7.51 billion in 2023 to $15.27 billion by 2028, driven by advancements in biologic therapies, personalized medicine, and product innovations. Key players include Sanofi SA, Regeneron Pharmaceuticals Inc., and Novartis International AG.
Alzheimer's Disease Therapeutics Companies | Best Treatments
Alzheimer’s disease therapeutics market includes symptomatic treatments (cholinesterase inhibitors, NMDA receptor antagonists) and disease-modifying therapies (anti-amyloid monoclonal antibodies). Market growth driven by aging population, diagnostic advancements, and R&D investments. Market expected to grow from USD 5.5 billion in 2023 to USD 30.8 billion by 2033 at 18.8% CAGR. Major companies include Biogen, Merck, GSK, Novartis, Johnson & Johnson, Bristol Myers Squibb, Sanofi, Pfizer, Teva Pharmaceutical, and AbbVie, each with strategic initiatives and collaborations in Alzheimer’s research.
FDA Grants Breakthrough Therapy Designation to Johnson & Johnson's Nipocalimab
Johnson & Johnson's nipocalimab receives FDA Breakthrough Therapy designation for treating moderate-to-severe Sjögren’s disease, based on Phase 2 DAHLIAS study results showing over 70% improvement in systemic disease activity. This marks the first investigational therapy for SjD to receive such designation, highlighting the need for innovative treatments in this chronic autoantibody disease.
Icotrokinra Delivered an Industry-Leading Combination of Significant Skin Clearance with Demonstrated Tolerability in a Once Daily Pill in Phase 3 Topline Results
Johnson & Johnson announced positive Phase 3 results for icotrokinra (JNJ-2113), showing significant skin clearance and tolerability in moderate to severe plaque psoriasis patients. Icotrokinra, a once-daily oral peptide targeting the IL-23 receptor, met co-primary endpoints of PASI 90 and IGA 0/1 at week 16, with response rates improving through week 24. Safety data aligned with previous studies, and further Phase 3 trials are ongoing.
Related Clinical Trials:
Johnson&Johnson's one-dose COVID-19 vaccine gets 'green light' from EU regulator
EMA recommends conditional marketing authorization for Janssen's single-dose COVID-19 vaccine, despite delivery delays until mid-April. The vaccine, fourth to be approved by the EU, showed 67% efficacy in a 44,000-person trial with common mild to moderate side effects.
From AI to Musk's brain chips, the FDA's device unit faces rapid change
AI-driven medical devices, including brain-computer interfaces by Elon Musk's Neuralink, are transforming healthcare, prompting increased FDA scrutiny. Dr. Michelle Tarver takes over the FDA's device division amid concerns over industry influence and ethical conflicts, particularly with former director Dr. Jeffrey Shuren's ties to the device industry. The FDA's reliance on industry user fees raises questions about public health protection versus industry profit. AI in healthcare, though promising, faces challenges in oversight and potential biases, with the FDA acknowledging its limitations in regulating the rapidly evolving field.
Lack of data on the vaccine, EMA postpones the approval of 'Sputnik V'
EU authorities to decide on Sputnik V vaccine use in September; Bavarian PM Markus Söder urges EMA for swift approval. Despite EMA's ongoing review, Hungary and Slovakia use Sputnik V without its permission.
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
OS Therapies, Inc. reported Q3 2024 financial results and completed Phase 2b trial of OST-HER2 in osteosarcoma, with topline data expected in December 2024.
J&J's nipocalimab shows promise in Phase II Sjögren's disease trial
Johnson & Johnson's Phase II DAHLIAS study of nipocalimab, an FcRn blocker, showed promising results in treating moderate-to-severe Sjögren’s disease, meeting primary and secondary endpoints, with significant improvements in ClinESSDAI scores and symptom relief.
© Copyright 2024. All Rights Reserved by MedPath